Generation and validation of a novel multitarget small molecule in glioblastoma

The development of multitarget small molecules (MSMs) has emerged as a powerful strategy for the treatment of multifactorial diseases such as cancer. Glioblastoma is the most prevalent and malignant primary brain tumor in adults, which is characterized by poor prognosis and a high heterogeneity. Current standards of treatment present limited effectiveness, as patients develop therapy resistance and recur. In this work, we synthesized and characterized a novel multi-target molecule (named DDI199 or contilistat), which is a polyfunctionalized indole derivative developed by juxtaposing selected pharmacophoric moieties of the parent compounds Contilisant and Vorinostat (SAHA) to act as multifunctional ligands that inhibit histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors. DDI199 exerts high cytotoxic activity in conventional glioblastoma cell lines and patient-derived glioma stem cells in vitro. Importantly, it significantly reduces tumor growth in vivo, both alone and in combination with temozolomide (TMZ). The comparison with SAHA showed higher target specificity and antitumor activity of the new molecule. Transcriptomic and proteomic analyses of patient-derived glioma stem cells revealed a deregulation in cell cycle, DNA remodeling and neurotransmission activity by the treatment with DDI199. In conclusion, our data reveal the efficacy of a novel MSM in glioblastoma pre-clinical setting.

Authors

Institutions

Publication Details

Journal
Cell Death and Disease
Published
2025-04-04
DOI
https://doi.org/10.1038/s41419-025-07569-1
Citations
4
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
3.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Generation and validation of a novel multitarget small molecule in glioblastoma

Alejandro Elúa-Pinin, Joseba Elizazu, Verónica Moncho-Amor, Ander Matheu et al.
4 citations
Cell Death and Disease
Histone Deacetylase Inhibitors Research
3.22
article

Generation and validation of a novel multitarget small molecule in glioblastoma

Alejandro Elúa-Pinin, Joseba Elizazu, Verónica Moncho-Amor, Ander Matheu, Linda Schäker‐Hübner, Isabel Iriepa, Mikel Azkargorta, Félix Elortza, Finn K. Hansen, Nicolàs Samprón, Francisco López‐Muñoz, Isabel Goñi, Nerea Iturrioz-Rodríguez, Jose Luis Marco-Contelles, Aizpea Artetxe-Zurutuza, Alicia Porro-Pérez, Mireia Toledano-Pinedo
article en
4 citations

Abstract

The development of multitarget small molecules (MSMs) has emerged as a powerful strategy for the treatment of multifactorial diseases such as cancer. Glioblastoma is the most prevalent and malignant primary brain tumor in adults, which is characterized by poor prognosis and a high heterogeneity. Current standards of treatment present limited effectiveness, as patients develop therapy resistance and recur. In this work, we synthesized and characterized a novel multi-target molecule (named DDI199 or contilistat), which is a polyfunctionalized indole derivative developed by juxtaposing selected pharmacophoric moieties of the parent compounds Contilisant and Vorinostat (SAHA) to act as multifunctional ligands that inhibit histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors. DDI199 exerts high cytotoxic activity in conventional glioblastoma cell lines and patient-derived glioma stem cells in vitro. Importantly, it significantly reduces tumor growth in vivo, both alone and in combination with temozolomide (TMZ). The comparison with SAHA showed higher target specificity and antitumor activity of the new molecule. Transcriptomic and proteomic analyses of patient-derived glioma stem cells revealed a deregulation in cell cycle, DNA remodeling and neurotransmission activity by the treatment with DDI199. In conclusion, our data reveal the efficacy of a novel MSM in glioblastoma pre-clinical setting.

Cell Death and DiseaseVol. 16(1)
Ikerbasque (ES), University of Bonn (DE), Instituto de Salud Carlos III (ES), Biogipuzkoa Health Research Institute (ES), Centre for Biomedical Network Research on Rare Diseases (ES), CIC bioGUNE (ES), HM Hospitales (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Instituto de Química Orgánica General (ES), University of Castilla-La Mancha (ES)
Deutsche Forschungsgemeinschaft, Eusko Jaurlaritza, Universidad Camilo José Cela, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación
Good health and well-being
Openalex Percentile: Top 9%
Histone Deacetylase Inhibitors Research
3.22
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.